Ra Capital Management, L.P. bought $1.7M of Tyra Biosciences (TYRA)
Executed Jun 12 2025, disclosed Jun 16 2025, 4 days later.
Over the 21 trading sessions from the disclosed entry session (Jun 16 2025), the stock returned +3.8% (delay-adjusted); from the execution session (Jun 12 2025), +5.7%. Derived: entry at the session's open, exit at the close 20 sessions later.
Ra Capital Management, L.P. (Director) filed 30 Form 4 reports as a reporting entity in the trailing twelve months (23 purchases, 7 sales, 1 filed past the two-business-day deadline), most often in Artiva Biotherapeutics, Inc. (ARTV). Across 23 priced purchase filings, the average 21-session return was +14.9% from execution and +14.0% from disclosure (delay-adjusted; derived). The largest single filing was $423.8M of PBLS (21,188,750 sh across 2 lots, as filed), executed Jun 11.